NASDAQ:CABA - Get Free Report )'s stock price rose 8.9% on Wednesday . The stock traded as high as $11.64 and last traded at $11.60. Approximately 934,421 shares changed hands during mid-day trading, a decline of 10% from the average daily volume of 1,037,752 shares. The stock had previously closed at $10.65.
Get Cabaletta Bio alerts:
Sign Up
Wall Street Analyst Weigh In CABA has been the topic of several analyst reports. Citigroup increased their target price on Cabaletta Bio from $26.00 to $30.00 and gave the company a "buy" rating in a research note on Thursday, April 4th. Cantor Fitzgerald restated an "overweight" rating and issued a $50.00 price target on shares of Cabaletta Bio in a report on Friday, April 5th. HC Wainwright increased their price target on Cabaletta Bio from $25.00 to $30.00 and gave the stock a "buy" rating in a report on Friday, March 22nd. Jefferies Financial Group initiated coverage on Cabaletta Bio in a report on Monday, February 5th. They issued a "buy" rating and a $36.00 price target for the company. Finally, Wells Fargo & Company increased their price target on Cabaletta Bio from $34.00 to $35.00 and gave the stock an "overweight" rating in a report on Friday, March 22nd. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $34.33.
Get Our Latest Stock Analysis on CABA
Cabaletta Bio Stock Up 16.6 % The firm has a market capitalization of $580.91 million, a P/E ratio of -7.52 and a beta of 2.41. The stock has a fifty day moving average of $17.80 and a 200-day moving average of $18.76.
Cabaletta Bio (NASDAQ:CABA - Get Free Report ) last posted its quarterly earnings data on Thursday, March 21st. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.07). Sell-side analysts predict that Cabaletta Bio, Inc. will post -1.82 EPS for the current fiscal year.
Institutional Inflows and Outflows A number of hedge funds have recently bought and sold shares of the stock. Amalgamated Bank grew its stake in Cabaletta Bio by 24.7% in the third quarter. Amalgamated Bank now owns 4,648 shares of the company's stock valued at $71,000 after purchasing an additional 922 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Cabaletta Bio by 65.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,623 shares of the company's stock valued at $60,000 after buying an additional 1,042 shares during the last quarter. Macroview Investment Management LLC acquired a new stake in shares of Cabaletta Bio in the fourth quarter valued at approximately $26,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Cabaletta Bio by 65.4% in the first quarter. China Universal Asset Management Co. Ltd. now owns 8,206 shares of the company's stock valued at $140,000 after buying an additional 3,244 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Cabaletta Bio by 29.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 16,798 shares of the company's stock valued at $256,000 after buying an additional 3,798 shares during the last quarter.
Cabaletta Bio Company Profile (
Get Free Report )
Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.
See Also Before you consider Cabaletta Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cabaletta Bio wasn't on the list.
While Cabaletta Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
